Winner Medical Group Inc., a leading manufacturer and exporter of medical, wound care and home care products in China, today announced that it has opened its first three PurCotton pilot chain stores in Shenzhen, Guangdong province, China on December 31, 2009.
Applied Nanotech Holdings, Inc. announced that it has entered into a License and Research and Development agreement related to its carbon nanotube composite technology (epoxy/CNT) with a prominent sporting goods manufacturer.
Today, Enel Green Power, Sharp and STMicroelectronics signed an agreement for the manufacture of triple-junction thin-film photovoltaic panels in Italy. At the same time, Enel Green Power and Sharp signed a further agreement to jointly develop solar farms.
mPhase Technologies, Inc. today announced that its consumer products division, mPower Technologies Inc., will unveil the mPower Emergency Illuminator at the 2010 International Consumer Electronics Show in Las Vegas, Nevada.
Investors and corporate licensees from Fortune 1000 companies will meet once again in Arlington, Texas for the eighth annual WBTshowcase (WBT2010), the world's largest forum offering a prescreened, pre-prepped collection of undiscovered companies and intellectual property emanating from top universities, labs and research institutions from across the country.
Dr Thierry Bontoux has stepped down from his position of Deputy Director of the LCN in charge of Business. His decision will be effective from the 31st of December 2009 and he will then focus on his new venture, TBx-Consulting.
Arrowhead Research Corporation today announced that its wholly owned subsidiary, Tego Biosciences, has completed a definitive asset purchase agreement for the sale of its non-cash intellectual property to Luna Innovations, Inc., a developer and manufacturer of new-generation products that include pharmaceutical nanomedicines.
Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects